Gemcitabine Hydrochloride

Antineoplastic agent Nucleoside analog (pyrimidine antimetabolite)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog IV 2-4 mg/kg (or 100-200 mg/m²) Weekly for 3 weeks, then 1 week rest; or every 2-3 weeks Duration: Variable; typically 3-6 cycles depending on response and toxicity
Notes: Administer as a 30-minute IV infusion. Dose reduction may be necessary for hematologic toxicity. Premedication with antiemetics may be considered.
Cat IV 1.5-2.5 mg/kg (or 100-150 mg/m²) Weekly for 3 weeks, then 1 week rest; or every 2-3 weeks Duration: Variable; typically 3-6 cycles
Notes: Cats may be more sensitive to myelosuppression; start at lower end of dose range. Monitor CBC closely.
Horse IV Not established; experimental doses of 2-5 mg/kg have been used Weekly Duration: Variable
Notes: Limited data; use with caution. May cause severe bone marrow suppression.
Other species IV Not established N/A Duration: N/A
Notes: Not recommended due to lack of safety and efficacy data.

Clinical Indications & Species Uses

General Indications
  • Antineoplastic agent for various malignancies; used as a single agent or in combination protocols
Dog (Canine)
  • Treatment of lymphoma (as part of multi-agent protocols)
  • Osteosarcoma (adjuvant or rescue therapy)
  • Mammary carcinoma
  • Transitional cell carcinoma (bladder)
  • Various solid tumors (off-label use)
Cat (Feline)
  • Lymphoma (rescue therapy)
  • Mammary carcinoma
  • Various solid tumors (off-label use)

Pharmacology & Mechanism of Action

Drug Class: Antineoplastic agent | Pharmacological Group: Nucleoside analog (pyrimidine antimetabolite)

Mechanism of Action: Gemcitabine is a deoxycytidine analog that requires intracellular phosphorylation to its active metabolites, gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). dFdCDP inhibits ribonucleotide reductase, depleting deoxyribonucleotide pools required for DNA synthesis. dFdCTP competes with deoxycytidine triphosphate for incorporation into DNA, leading to chain termination and apoptosis. Additionally, gemcitabine may inhibit thymidylate synthase and other enzymes, contributing to its cytotoxic effects.

Pharmacodynamics: Gemcitabine is cell-cycle specific, primarily acting during the S-phase of the cell cycle. It exhibits antitumor activity against a broad range of solid tumors and hematologic malignancies. In veterinary patients, it has shown activity against lymphoma, osteosarcoma, mammary carcinoma, and other neoplasms. Its efficacy is schedule-dependent, with more frequent dosing often leading to increased toxicity without improved efficacy.

⚡ Pharmacokinetics Summary

Absorption: Gemcitabine is poorly absorbed orally; therefore, it is administered intravenously. After IV administration, peak plasma concentrations are achieved rapidly.
Distribution: Gemcitabine is widely distributed into tissues, including tumor tissues. It has a relatively small volume of distribution (Vd) in humans (about 50 L/m²), but species-specific data are limited. It crosses the blood-brain barrier minimally.
Metabolism: Gemcitabine is extensively metabolized intracellularly to active and inactive metabolites. It is deaminated by cytidine deaminase in the liver, blood, and other tissues to the inactive metabolite 2',2'-difluorodeoxyuridine (dFdU).
Excretion: The primary route of elimination is renal excretion of the inactive metabolite dFdU. In humans, about 99% of the dose is excreted in urine, with less than 10% as unchanged drug. Biliary excretion is minimal.
Half-Life: The terminal half-life of gemcitabine is short (approximately 10-20 minutes in humans), but the active triphosphate has a longer intracellular half-life (hours to days). In dogs, the half-life is approximately 30-60 minutes.
Bioavailability: Oral bioavailability is negligible (<10%) due to extensive first-pass metabolism; therefore, it is only administered parenterally.
Protein Binding: Gemcitabine is minimally bound to plasma proteins (<10%).

Available Formulations & Strengths

Lyophilized powder for injection 200 mg, 1 g, 2 g vials (IV)
Reconstituted solution (with 0.9% NaCl) Concentration after reconstitution: 38 mg/mL (200 mg vial) or 100 mg/mL (1 g vial) (IV)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to gemcitabine or any component of the formulation
  • Severe bone marrow suppression (neutrophils < 1,500/µL, platelets < 100,000/µL)
  • Severe hepatic or renal impairment (use with caution)
  • Pregnancy or lactation (teratogenic and embryotoxic)
  • Concurrent use with live vaccines
Warnings & Clinical Precautions:
  • Myelosuppression is dose-limiting; monitor complete blood count (CBC) regularly.
  • Hepatotoxicity and nephrotoxicity may occur; monitor liver enzymes and renal function.
  • Extravasation may cause tissue necrosis; administer via a secure IV catheter.
  • Immunosuppression may increase risk of infections.
  • Use with caution in patients with pre-existing hepatic or renal disease.
  • Teratogenic; handle with caution in pregnant personnel.
  • May cause gastrointestinal toxicity (nausea, vomiting, diarrhea).
  • In cats, monitor for signs of neurotoxicity (rare).

Adverse Effects & Reactions

Common:

  • Myelosuppression (neutropenia, thrombocytopenia, anemia)
  • Gastrointestinal signs (vomiting, diarrhea, anorexia)
  • Lethargy
  • Elevated liver enzymes

Serious / Severe:

  • Severe neutropenia with fever (febrile neutropenia)
  • Thrombocytopenia with bleeding
  • Hepatotoxicity
  • Nephrotoxicity
  • Pulmonary toxicity (rare)
  • Hemolytic-uremic syndrome (rare)

Rare:

  • Allergic reactions
  • Neurotoxicity
  • Cardiotoxicity
  • Secondary malignancies

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other myelosuppressive agents (e.g., doxorubicin, cyclophosphamide) Additive bone marrow suppression; dose reduction may be required. High
Warfarin and other anticoagulants May increase anticoagulant effect; monitor coagulation parameters. Moderate
Live vaccines Immunosuppression may lead to vaccine-induced infection; avoid concurrent use. High
Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) Increased risk of renal toxicity; monitor renal function. Moderate
Hepatotoxic drugs (e.g., azathioprine) Increased risk of hepatotoxicity; monitor liver enzymes. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe myelosuppression (pancytopenia)
  • Gastrointestinal toxicity (severe vomiting, diarrhea)
  • Hepatotoxicity
  • Nephrotoxicity
  • Neurotoxicity (rare)

Emergency Treatment Protocol: There is no specific antidote for gemcitabine overdose. Treatment is primarily supportive and symptomatic. Hospitalization may be required. Monitor CBC, liver enzymes, and renal function. Administer antiemetics, IV fluids, and blood products as needed. Consider granulocyte colony-stimulating factor (G-CSF) for severe neutropenia. In severe cases, dialysis may be considered for renal failure.

Food Animal Withdrawal Times

Gemcitabine is not approved for use in food animals. Use in food animals is prohibited due to potential carcinogenicity and lack of withdrawal data. Do not use in animals intended for human consumption.

Storage, Handling & Regulatory Information

Storage Temperature: Store lyophilized powder at controlled room temperature (20-25°C). Reconstituted solution is stable for 24 hours at room temperature or 7 days under refrigeration (2-8°C). Do not freeze.

Handling & Special Conditions: Protect from moisture. Reconstituted solution should be used within the specified time. Discard unused portions.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not approved for veterinary use; approved for human use (Gemzar®).

Extra-Label (Off-Label) Use: In the US, gemcitabine is not FDA-approved for veterinary use. Its use in animals is considered extra-label and must comply with AMDUCA regulations. For food animals, extra-label use is prohibited if the drug is not approved for that species and if there are no established withdrawal times.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Gemcitabine is a valuable chemotherapeutic agent in veterinary oncology, particularly for dogs and cats with lymphoma, osteosarcoma, and other solid tumors. It is often used as a rescue agent when first-line therapies fail. Due to its myelosuppressive effects, close monitoring of blood counts is essential. The drug is administered intravenously, and extravasation must be avoided. Dosing is typically based on body surface area (mg/m²) or body weight (mg/kg), with cats requiring lower doses. Combination protocols may enhance efficacy but increase toxicity. Always use appropriate safety precautions when handling and administering chemotherapeutic agents. Consult a veterinary oncologist for specific treatment protocols and management of adverse effects.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)